Bridgewater, New Jersey, U.S., September 21, 2026
Insmed has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental New Drug Application (sNDA) seeking approval of ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease in patients whose disease has remained positive despite an appropriate multidrug background regimen. The FDA has assigned a PDUFA target action date of January 28, 2027, establishing the next major regulatory milestone for the supplemental application. ARIKAYCE is already approved in the United States for a specific population of adults with refractory MAC lung disease as part of a combination antibacterial regimen, and the new application seeks to expand the medicine’s use based on additional clinical evidence. The Priority Review designation means the FDA aims to complete its review within a shorter timeframe than the standard review process, although it does not guarantee approval.
FDA Priority Review Advances ARIKAYCE Application
The FDA’s Priority Review designation reflects the agency’s determination that the supplemental application could provide a significant improvement in safety or effectiveness in the treatment of a serious condition compared with available therapies. Insmed submitted the sNDA following clinical data evaluating ARIKAYCE in patients with MAC lung disease who continue to have positive cultures despite multidrug antibiotic treatment. The regulatory filing is intended to support an expanded indication for the inhaled formulation and potentially provide physicians with an additional treatment option for patients facing persistent disease.
ARIKAYCE is a liposomal formulation of amikacin designed for delivery directly to the lungs through oral inhalation. The formulation uses liposomes to encapsulate the aminoglycoside antibiotic, allowing the medicine to be administered directly to the site of pulmonary infection. The approach is particularly relevant to MAC lung disease, a chronic pulmonary infection caused by bacteria belonging to the Mycobacterium avium complex. Treatment can be prolonged and often involves multiple antimicrobial medicines, while some patients continue to have positive cultures despite therapy.
ARIKAYCE Targets Refractory MAC Lung Disease
Advertisement
MAC lung disease can cause persistent respiratory symptoms, lung damage and progressive decline in pulmonary function in affected patients. Individuals may experience chronic cough, fatigue, shortness of breath and reduced exercise capacity, while the disease can be particularly challenging to manage when bacterial cultures remain positive despite treatment. ARIKAYCE was developed to deliver amikacin directly into the lungs, providing localized exposure to the antibacterial agent. The proposed expanded indication focuses on patients with refractory MAC lung disease, representing a population with an ongoing medical need. Insmed’s supplemental application is supported by clinical evidence from its development program evaluating ARIKAYCE in combination with background antimicrobial therapy. The regulatory review will determine whether the submitted evidence supports expansion of the medicine’s U.S. indication. The FDA has set January 28, 2027, as the PDUFA target action date, when the agency is expected to complete its review and communicate a regulatory decision. The date represents a target for FDA action rather than a guarantee that the application will be approved. The final decision will depend on the agency’s assessment of the submitted clinical, safety, efficacy and manufacturing information.
Insmed Advances MAC Treatment Development
The Priority Review represents another regulatory milestone for Insmed’s ARIKAYCE program, which is focused on addressing serious respiratory infections. The company has continued to develop the medicine as part of its strategy to address diseases affecting patients with significant treatment challenges. ARIKAYCE’s inhaled delivery approach is intended to provide high concentrations of amikacin within the lungs while forming part of a broader multidrug treatment regimen. If approved for the proposed expanded indication, ARIKAYCE could potentially become available to a broader population of patients with MAC lung disease in the United States. However, the medicine’s ultimate regulatory status will depend on the FDA’s forthcoming decision. Until then, the Priority Review designation marks an important step in the ongoing regulatory process. For cGxP.wire readers, the announcement highlights developments in FDA regulatory review, supplemental drug applications, antibiotic therapy, pulmonary infections, rare and difficult-to-treat diseases, and pharmaceutical innovation. The January 2027 PDUFA date will provide the next key milestone for Insmed and patients awaiting a potential expansion of ARIKAYCE’s use in refractory MAC lung disease.
Source: Insmed press release
